Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: The Veterans LAST study (Lutein Antioxidant Supplementation Trial)

Optometry

Volumn 75, Issue 4, 2004, Pages 216-229

  Richer, Stuart ^a,c,f   Stiles, William ^a   Statkute, Laisvyde ^a,d   Pulido, Jose ^b   Frankowski, James ^a,e   Rudy, David ^c   Pei, Kevin ^c   Tsipursky, Michael ^c   Nyland, Jill ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d Jr Hospital of Cook County   (United States)

^e American Academy of Orthopaedic Surgeons   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Age related macular degeneration; Antioxidants; Lutein; Nutrition

Indexed keywords

ANTIOXIDANT; MALTODEXTRIN; MINERAL; PLACEBO; VISUAL PIGMENT; VITAMIN; XANTHOPHYLL;

AGED; ARTICLE; CLINICAL TRIAL; CONTRAST SENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLARE; HUMAN; MALE; OPHTHALMOLOGY; OPTICAL DENSITY; PATIENT REFERRAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; URBAN AREA; VISUAL ACUITY; VITAMIN SUPPLEMENTATION; CASE CONTROL STUDY; COMPARATIVE STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; PATHOPHYSIOLOGY; RETINA MACULA DEGENERATION; TREATMENT OUTCOME;

AGED; ANTIOXIDANTS; CASE-CONTROL STUDIES; CONTRAST SENSITIVITY; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLARE; HUMANS; LUTEIN; MACULAR DEGENERATION; MALE; MINERALS; TREATMENT OUTCOME; VISUAL ACUITY; VITAMINS;

EID: 2542432254     PISSN: 15291839     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1529-1839(04)70049-4     Document Type: Article

References (65)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Study. Ophthalmology 1992;99:933-43.
2. Klein R, Klein B, Jensen S. The five-year incidence and progression of age-related maculopathy: The Beaver Dam Study. Ophthalmology 1997;104:7-21.
3. Ryan S. Age-related macular degeneration. Retina, vol. 2. St. Louis: CV Mosby, 1994.
4. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol 1996;80:9-14.
5. Maruo T, Ikebukuro N, Kawanabe K, et al. Changes in causes of visual handicaps in Tokyo. Jpn J Ophthalmol 1991;35:268-72.
6. Weeks DE, Conley YP, Tsai HJ, et al. Age-related maculopathy: an expanded genome-wide scan with evidence of susceptability loci within the 1q31 and 17q25 regions. Am J Ophthalmol 2001;132:682-92.
7. Christen W, Glynn R, Manson J, et al. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA 1996;276:1147-51.
8. Seddon J, Willett W, Speizer F, et al. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996;276:1141-6.
9. Handelman G, Packer L, Cross C. Destruction of tocopherols, carotenoids, and retinol in human plasma by cigarette smoke. Am J Clin Nutr 1996;63:559-65.
10. Hammond B, Wooten B, Snodderly D. Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vis Res 1996;36:3003-9.
11. Lerman S. Photosensitizing drugs and their possible role in enhancing ocular toxicity. Ophthalmology 1986;93:304-18.
12. Khachik F, Bernstein P, Garland D. Identification of lutein and zeaxanthin oxidation products in human and monkey retina. Invest Ophthalmol Vis Sci 1997;38:1802-11.
13. Organisciak D, Darrow R, Barsalou L. Light history and age-related changes in retinal light damage. Invest Ophthalmol Vis Sci 1998;39:1107-16.
14. Sujak A, Gabrielska J, Grudzinski W, et al. Lutein and zeaxanthin as protectors of lipid membranes against oxidative damage: the structural aspects. Arch Biochem Biophys 1999;371:301-7.
15. Goldberg J, Flowerdew G, Smith E, et al. Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol 1988;128:700-10.
16. Seddon J, Ajani U, Sperduto R, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 1994;272:1413-20. Erratum in: JAMA 1995;273:622.
17. Pagliarini S, Moramarco A, Wormald R, et al. Age-related macular disease in rural southern Italy. Arch Ophthalmol 1997;115:616-22.
18. Age-related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 9. Arch Ophthalmol 2001;119: 1439-52.
19. Jampol LM. Antioxidants, zinc, and age-related macular degeneration. Results and recommendations (editorial). Arch Ophthalmol 2001;119:1533-4.
20. Age-related Macular Degeneration Study Group. Multicenter ophthalmic/nutritional ARMD Study - Part 1: Design, subjects, and procedures. J AM OPTOM ASSOC 1996;67:12-29.
21. Richer S. Multicenter ophthalmic and nutritional age-related macular degeneration study - Part 2: Antioxidant intervention and conclusions. J AM OPTOM ASSOC 1996;67:30-49.
22. Pratt S. What is lutein, and what is its role in the macula. Paper presented at: Age-related macular degeneration (AMD) and lutein: assessing the evidence. London: Royal Society of Medicine, June 7, 2001.
23. Shao A. The role of lutein in human health. JAMA 2001;4:8-24.
24. Dwyer J, Navab M, Dwyer K, et al. Oxygenated carotenoid lutein and progression of early atherosclerosis: The Los Angeles Atherosclerosis Study. Circulation 2001;103:2922-7.
25. Hammond BR Jr, Fuld K, Snodderly DM. Iris color and macular pigment optical density. Exp Eye Res 1996;62:293-7.
26. Hammond BR Jr, Curran-Celentano J, Judd S, et al. Sex differences in macular pigment optical density: relation of plasma carotenoid concentrations and dietary patterns. Vis Res 1996;36:2001-12.
27. Bone RA, Landrum JT, Mayne ST, et al. Macular pigment in donor eyes with and without AMD: a case control study. Invest Ophthalmol Vis Sci 2001;42:235-40. Erratum in: Invest Ophthalmol Vis Sci 2001;42:548.
28. Beatty S, Murray JJ, Henson DB, et al. Macular pigment and risk for age-related macular degeneration in subjects from a northern European population. Invest Ophthalmol Vis Sci 2001;42:439-46.
29. Schalch W. Carotenoids in the retina - a review of their possible role in preventing or limiting damage caused by light and oxygen. Switzerland: Birkhauser Verlag Basel, 1992.
30. Pratt S. Dietrary prevention of age-related macular degeneration. J AM OPTOM ASSOC 1999;70:39-47.
31. Snodderly DM. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr 1995;62(Suppl):1448s-1461s.
32. Midena E, Degli Angeli C, Blarzino MC, et al. Macular function impairment in eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci 1997;38:469-77.
33. Richer S. Part I: A protocol for the evaluation and treatment of atrophic age-related macular degeneration. J AM OPTOM ASSOC 1999;70:13-23.
34. Hammond BR Jr, Johnson EJ, Russel RM, et al. Dietary modification of human macular pigment density. Invest Ophthalmol Vis Sci 1997;38:1795-801.
35. Richer S. Part II: ARMD-Pilot (case series) environmental intervention data. J AM OPTOM ASSOC 1999;70:24-36.
36. Willett W. Assessment of antioxidant intake in epidemiological studies: Department of Nutrition, Harvard School of Public Health. ARVO, Ft. Lauderdale, Florida, #899.
37. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985;122:51-65.
38. Chylack LT. Function of the lens and methods of quantifying cataract. In: Taylor A, ed. Nutritional and environmental influences on the eye. Boca Raton, Fla.: CRC Press, 1999:25-52.
39. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367-74.
40. Wooten BR, Hammond BR Jr, Land R, et al. A practical method for measuring macular pigment optical density. Invest Ophthalmol Vis Sci 1999;40:2481-9.
41. Haegerstrom-Portnoy G, Brabyn J, Schneck ME, et al. The SKILL Card: an acuity test of reduced luminance and contrast. Invest Ophthalmol Vis Sci 1997;38:207-18.
42. Glaser JS, Savino PJ, Sumers KD, et al. The photostress recovery test in the clinical assessment of visual function. Am J Ophthalmol 1977;83:255-60.
43. Haegerstrom-Portnoy G. Personal communication, 1999.
44. Haegerstrom-Portnoy G, Schneck ME, Brabyn JA. Seeing into old age: vision function beyond acuity. Optom Vis Sci 1999;76:141-58.
45. Jindra LF, Zemon V. Contrast sensitivity testing: a more complete assessment of vision. J Cataract Refract Surg 1989;15:141-8.
46. Mantyjarvi M, Laitinen T. Normal values for the Pelli-Robson contrast sensitivity test. J Cataract Refract Surg 2001;27:261-6.
47. Mangione CM, Phillips RS, Seddon JM, et al. Development of the 'Activities of Daily Vision Scale.' A measure of visual functional status. Med Care 1992;30:1111-26.
48. Kirk R. Experimental design, 2nd ed. Pacific Grove, Calif.: Brooks/Cole Publishing Company, 1982.
49. Richer S, Statkute L, Frankowski J, et al. Simple contrast sensitivity (CSF) testing at 3 cc/degree is a surrogate marker for human macula pigment density. DVA Medical Center, North Chicago, Ill.: ARVO, 2001, Ft. Lauderdale, Florida, #3804.
50. Hammond BR Jr, Ciulla TA, Snodderly DM. Macula pigment density is reduced in obese subjects. Invest Ophthalmol Vis Sci 2002;43:47-50.
51. Berson EL. Nutrition and retinal degenerations. Int Ophthalmol Clin 2000;40:93-111.
52. Newsome DA, Swartz M, Leone NC, et al. Oral zinc in macular degeneration. Arch Ophthalmol 1988;106:192-8.
53. van den Berg H. Carotenoid interactions. Nutr Rev 1999;57:1-10.
54. Thurnham DI, Northrop-Clewes CA. Optimal nutrition: vitamin A and the carotenoids. Proc Nutr Soc 1999;58:449-57.
55. Paiva SA, Russell RM. Beta-carotene and other carotenoids as antioxidants. J Am Col Nutr 1999;18:426-33.
56. Castenmiller JJ, West CE. Bioavailability and bioconversion of carotenoids. Ann Rev Nutr 1998;18:19-38.
57. Palace VP, Khaper N, Qin Q, et al. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Free Radic Biol and Med 1999;26:746-61.
58. Pratt VP, Richer S, Tornabe P, et al. Macula pigment density is negatively correlated with glare recovery in female patients with normal acuity. Scripps Institute of Integrative Medicine. ARVO 2002, Ft. Lauderdale, Florida, #2540.
59. Beatty S, Boulton M, Henson D. Macular pigment and age-related macular degeneration. Br J Ophthalmol 1999;83:867-77.
60. Snodderly DM, Auran JD, Delori F, et al. The macular pigment. II. Spatial distribution in primate retinas. Invest Ophihalmol Vis Sci 1984;25:674-85.
61. de Fez MD, Luque MJ, Viqueira V. Enhancement of contrast sensitivity and losses of chromatic discrimination with tinted lenses. Optom Vis Sci 2002;79:590-7.
62. Sommerburg OG, Siems WG, Hurst JS, et al. Lutein and zeaxanthin are associated with photoreceptors in the human retina. Curr Eye Res 1999;19:491-5.
63. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the retinal pigment epithelium. Eye 1988;2:552-77.
64. Williams RA, Brody BL, Thomas RG, et al. The psychosocial impact of macular degeneration. Arch Ophthalmol 1998;116:514-20.
65. Richer S, Rudy D, Statkute L, et al. Serum iron, transferrin saturation, ferritin, and dietary data in age-related macular degeneration. Am J Ther 2002;9:25-8.